Post

Comorbidities associated with ADHD present an opportunity for pipeline products

Attention deficit hyperactivity disorder (ADHD) is a clinically heterogeneous disorder, with published research often putting comorbidity estimates at between 60%–80%. …

The magrolimab trial halt highlights the uncertainties in anti-CD47 immunotherapy

Since January 2022, Gilead Sciences has either discontinued or put on hold multiple Phase III clinical trials (NCT04313881, NCT04778397, NCT05079230) …

Intelligent Bio Solutions seeks 510(k) approval with drug screening study

US-based medical technology company Intelligent Bio Solutions Inc (INBS) has teamed up with clinical research organisation (CRO) Cliantha Research to …

Palatin to push through with dry eye therapy despite Phase III miss

Palatin Technologies has released Phase III MELODY-1 trial results for its dry eye therapy, PL9643. The drug failed to meet …

Myocardial Infarction: Three drug trials to watch in 2024

Myocardial infarction (MI), known commonly as a heart attack, is one of the major causes of death globally and can …